Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer

Journal of Clinical Oncology

Volumn 18, Issue 15, 2000, Pages 2869-2880

  Kestin, Larry L ^a   Martinez, Alvaro A ^a   Stromberg, Jannifer S ^a   Edmundson, Gregory K ^a   Gustafson, Gary S ^a   Brabbins, Donald S ^a   Chen, Peter Y ^a   Vicini, Frank A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRIDIUM 192; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; AGED; ARTICLE; BEAM THERAPY; BRACHYTHERAPY; ECHOGRAPHY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE;

EID: 0033860233     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.15.2869     Document Type: Article

References (98)

1. Brachytherapy boost techniques for locally advanced prostate cancer
2. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer
3. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy
4. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions
5. Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > 10 ng/ml
6. Locally advanced prostate cancer: Long-term toxicity outcome after three-dimensional conformal radiation therapy - A dose escalation study
7. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer
8. The experience with neutron irradiation in locally advanced adenocarcinoma of the prostate
9. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
10. Beneficial effect of combination hormonal therapy administered prior and following external beam irradiation in localized prostate cancer
11. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31
12. Androgen deprivation with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the radiation therapy oncology group
13. Pd 103 brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma
14. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma
15. High dose combination radiotherapy for the treatment of localized prostate cancer
16. Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma
17. Irradiation of localized prostatic carcinoma with a combination of high dose rate iridium-192 brachytherapy and external beam radiotherapy with three target definitions and dose levels inside the prostate gland
18. High-dose rate interstitial with external beam irradiation for localized prostate cancer: Results of a prospective trial
19. High dose-rate brachytherapy of prostate cancer: German experience
20. High dose-rate after-loading iridium-192 prostate brachytherapy: Feasibility report
21. Iridium-192 high-dose-rate brachytherapy: A useful alternative therapy for localized prostate cancer?
22. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: Superior prostate-specific antigen response compared with external beam treatment
23. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation
24. PSA relapse definitions: The Vancouver Rules show superior predictive power
25. The correlation of serial prostate-specific antigen measurements with clinical outcome in the treatment of prostate cancer with external beam radiotherapy
26. Defining biochemical failure for prostate cancer treated with external beam radiation therapy
27. Consensus statement: Guidelines for PSA following radiation therapy
28. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control
29. Prostate
30. Conformal prostate brachytherapy: Initial experience of a phase I/II clinical trial
31. Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: Treatment description and preliminary results of a phase I/II clinical trial
32. Geometry based optimization for stepping source implants
33. Concurrent treatment planning for outpatient high dose rate prostate template implants
34. Intraoperative optimization of needle placement and dwell times for conformal prostate brachytherapy
35. Introduction to HDR optimization
36. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses
37. Defining biochemical cure for prostate cancer treated with external beam radiation therapy
38. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer
39. Nonparametric estimation from incomplete observations
40. Regression models and life-tables
41. Evaluation of survival data and two new rank order statistics arising in its consideration
42. Fractionation and protraction of radiotherapy of prostate carcinoma
43. Prostate-specific antigen nadir of 0.5 ng/ml or less defines disease freedom for surgically staged men irradiated for prostate cancer
44. Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate
45. Results of radical prostatectomy in men with locally advanced prostate cancer: Multi-institutional pooled analysis
46. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
47. Radiation inactivation of human prostate cancer cells: The role of apoptosis
48. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy
49. In vitro radiation sensitivity of the LNCaP prostatic tumor cell line
50. The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma
51. Prostate-specific antigen nadir: The optimum level after irradiation for prostate cancer
52. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer
53. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systemic biopsy and serum prostate specific antigen
54. Serum prostate-specific antigen profile following radiotherapy for prostate cancer: Implications for patterns of failure and definition of cure
55. PSA after definitive radiotherapy for clinically localized prostate cancer
56. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: The relationship between nadir level and disease free survival
57. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy
58. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer
59. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate
60. Optimization of conformal radiation treatment of prostate cancer: Report of a dose escalation study
61. External beam radiotherapy for stage T1/T2 prostate cancer: How does it stack up?
62. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate
63. Conformal mixed neutron and photon irradiation in localized and locally advanced prostate cancer: Preliminary estimates of the therapeutic ratio
64. Photon neutron mixed-beam radiotherapy of locally advanced prostate cancer
65. Preliminary results of a hyperfractionated dose escalation study for locally advanced adenocarcinoma of the prostate
66. Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone
67. Combined proton and photon conformal radiation therapy for locally advanced carcinoma of the prostate: Preliminary results of a phase I/II study
68. A dose-response study for I-125 prostate implants
69. Long-term results of retropubic permanent iodine-125 implantation of the prostate for clinically localized prostate cancer
70. External beam radiotherapy in cancer of the prostate: The University of Arizona experience
71. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: Analysis of RTOG 77-06
72. Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06: A phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma
73. Carcinoma of the prostate: Treatment with external radiotherapy
74. Prostate carcinoma: Radiation treatment of the primary and lymphatics
75. Megavoltage radiation therapy for carcinoma of the prostate
76. Elective pelvic nodal irradiation in patients with clinically localized prostate cancer at high risk for pelvic nodal involvement
77. Radiotherapy for prostate carcinoma: The JCRT experience (1968-1978) - II. Factors related to tumor control and complications
78. Does pelvic irradiation play a role in the management of prostate cancer?
79. Stage C adenocarcinoma of the prostate: An analysis of 551 patients treated with external beam irradiation
80. Status of radiation treatment of prostate cancer at Stanford University
81. The value of external field radiation therapy in carcinoma of the prostate
82. Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate
83. Comparison of whole pelvis versus small-field radiation therapy for carcinoma of the prostate
84. Local control and survival after external irradiation for adenocarcinoma of the prostate
85. Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer
86. Identification of a high-risk localized prostate cancer subgroup receiving maximum benefit from whole-pelvic irradiation
87. Treatment of prostate cancer with goserelin and radiotherapy
88. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores
89. A comparison of external beam radiation therapy versus radical prostatectomy in patients with low-risk prostate cancer diagnosed, staged, and treated at a single institution
90. Prostatic adenocarcinoma occurring in men under 50 years of age
91. Patterns of Care Outcome Studies: Results of national practice in adenocarcinoma of the prostate
92. Factors influencing outcome of definitive radiotherapy for localized carcinoma of the prostate
93. Prognostic factors in carcinoma of the prostate: Analysis of RTOG study 75-06
94. Use of systematic biopsy results to predict pathologic stage in patients with clinically localized prostate cancer: A preliminary report
95. Ability of sextant biopsies to predict radical prostatectomy stage
96. Treatment of prostate cancer using a proactive decision-making process
97. Managing geometric uncertainty in conformal intensity-modulated radiation therapy
98. The use of adaptive radiation therapy to reduce setup error: A prospective clinical study